Surgical therapy of ovarian cancer
Authors:
J. Chovanec; R. Feranec; M. Náležinská; T. Cacek
Authors place of work:
Oddělení gynekologické onkologie, Klinika operační onkologie MOU a LF Masarykovy univerzity Brno
přednosta: doc. MUDr. R. Šefr, Ph. D.
Published in the journal:
Rozhl. Chir., 2017, roč. 96, č. 6, s. 237-241.
Category:
Review
Summary
Epithelial ovarian cancer remains the most lethal gynecologic malignancy in the Czech Republic. Due to the nonspecific symptoms of the disease, most cases are diagnosed only in advanced stages. The first line of treatment for ovarian cancer involves primary cytoreductive surgery, followed by combined adjuvant chemotherapy based on platinum and paclixatel, which generally achieves a good therapeutic response. However, in about two thirds of the patients, the disease relapses.
Key words:
ovarian cancer − cytoreductive surgery
Zdroje
1. SVOD: Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita 2005, dostupný z WWW: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802–8861.
2. Dundr P. Prekancerózy endometria, děložní tuby a ovaria: přehled současné problematiky. Česko-slovenská patologie 2012;1:30–4.
3. Sjoquist KM, Martyn J, Edmondson R, et al. The role of hormonal therapy in gynecological cancers-current status and future directions. Int J Gynecol Cancer 2011;21:1328−33.
4. Engelen MJ, Snel BJ, Schapveld M, et al. Long-term morbidity of adjuvant whole abdominal radiotherapy (WART) or chemotherapy for early stage ovarian cancer. Eur J Cancer 009;45:1193−1200.
5. Burger RA. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473−83.
6. Ramirez I, Chon HS, Apte SM. The role of surgery in the management of epithelial ovarian cancer. Cancer Control 2011;18:22–30.
7. Meigs JV.Tumor sof the female pelvic organs. New York, Mc Millan 1934.
8. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advance epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 2009;115:1234–44.
9. Skírnisdóttir I, Sorbe B. Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma. Int J Oncol 2007;30:727−34.
10. Van Der Burg M, Van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organisation for Research and Treatment of Cancer. New Engl J Med 1995;332:629−34.
11. Rose P, Nerenstone C, Brady M, et al. Secondary surgical cytoreduction for advanced ovarian Carcinoma. N Engl J Med 2004;351:2489−97.
12. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006;103:1070−6.
13. Vergote I, van Gorp T. Timing of debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer 2008;18 Suppl 1:11−9.
14. Vergote I, Trope C, Amant F, et al. Neoadjuvant chemotherapy of primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943−53.
15. Rosen B, Laframboise S, Ferguson S, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol 2014;134:462−7.
16. Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 2005;92:1026−32.
17. Harter P. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO Austria, and MITO. Int J Gynecol Cancer 2011;21:289−95.
18. Chi DS, McCaughty K, Diaz JP. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;109:1933−9.
19. Gouy S, Chereau E, Custodio AS, et al. Surgical procedures and morbidites of diaphragmatic surgery in patients undergoing initial or interval debulking surgery for advanced-stage ovarian cancer. J Amer College Surg 2010;210,509−14.
20. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cance: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d´Investigateurs Nationaux Pour les Etudes des Cancers de I´Ovaire (GINECO). Cancer 2009;115:1234–44.
Štítky
Surgery Orthopaedics Trauma surgeryČlánok vyšiel v časopise
Perspectives in Surgery
2017 Číslo 6
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Obstructed defecation syndrome – review article
- Malignant tumors of the small bowel
- Surgical therapy of ovarian cancer
- Total pelvic exenteration – strategy and extent of surgery